Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch & Poster Display session

40P - Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine

Date

12 Dec 2019

Session

Lunch & Poster Display session

Presenters

Alexandre Tavartkiladze

Citation

Annals of Oncology (2019) 30 (suppl_11): xi12-xi15. 10.1093/annonc/mdz448

Authors

A.A. Tavartkiladze1, R. Khutsishvili2, P. Revazishvili2, M. Maisuradze2, L. Tavartkiladze2, G. Tavartkiladze2

Author affiliations

  • 1 Medical Oncology And Hematology Department, Institute For Personalized Medicine, 0186 - Tbilisi/GE
  • 2 Medical Oncology, Institute for Personalized Medicine, 0186 - Tbilisi/GE
More

Resources

Abstract 40P

Background

Adoptive cell therapy is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. We report the successful treatment for the patients with recurrent Gastrointestinal Stromal Tumors (GIST) with adoptive cellular immunotherapy and personalized vaccine.

Methods

A total of 8 patients (aged from 29 to 54 years) with GIST. The patients with recurrent progressive disease refractory to aggressive multi-modality therapy including repetitive surgical resection, radiation, and chemotherapy and all lines targeted therapy. They received multiple courses of systemic intravenous administration of allogenous phytohemagglutinin (PHA) activated T-lymphocytes in combination with a low dose of interleukin-2 (IL-2) and personalized vaccine, which was adopted in laboratory from donors B-lymphocytes and Patient’s Circulated Tumor Cells.

Results

The side-effects of this treatment were limited and manageable. Among 8 patients, 5 achieved a complete remission (p < 0,001 as compared to the 3 noncomplete response patients) , as demonstrated by MRI after 2 months from initiation of immune therapy and confirmed by glucose-positron emission tomography (PET) imaging 7 months after initiation of immune therapy. After 14 months of follow-up, the 5 patients are still in remission with improving performance status. 2 patients showed disease progression during the treatment in the liver and both lungs too as multiple metastases and only one patient had disease stabilization.

Conclusion

Adoptive cellular immunotherapy utilizing allogenous phytohemagglutinin (PHA) activated T-lymphocytes and personalized vaccine with low dose IL-2 appears to be a safe and effective therapy for a subset of patients with primary, recurrent or progressive Gastrointestinal Stromal Tumors following conventional therapy.

Clinical trial identification

Editorial acknowledgement

Paris Descartes University

Paris Sorbonne University

Tbilisi State Medical University

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.